Novo Nordisk
Novo Nordisk shares jump almost 8% after US approves Wegovy pill
The approval gives the drugmaker a first-mover advantage in the race for a potent oral weight-loss medicine
What Novo Nordisk, OpenAI and Pop Mart have in common
All three have suffered the curse of overnight success
Novo gets 15 billion euros of orders for Akero acquisition bonds
This is more than triple the amount the Danish drugmaker is seeking
Metsera accepts Pfizer’s US$10 billion bid in ongoing M&A battle
OBESITY drug developer Metsera said on Friday that it had accepted Pfizer’s US$10 billion acquisition offer, in what could spell the end of a bidding war between the New York-based pharma giant and ri...
Novo Nordisk lowers full-year profit guidance in new CEO’s maiden quarter
The firm says it now expects full-year operating profit to grow between 4% and 7% in 2025
Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid
[BENGALURU] Pfizer on Friday (Oct 31) filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s US$8.5 billion bid ...
How I knew when to start backing Novo Nordisk’s biggest rival instead
The Danish firm’s complacency is its undoing in the weight-loss drug war
Ozempic-maker Novo Nordisk to cut 9,000 jobs in restructuring
The company currently has 78,400 positions globally
Singapore’s KPB Biosciences fails in bid to unfreeze assets in US$830 million Novo Nordisk legal battle
The Danish drugmaker alleges that KPB misled it about its drug for hypertension and kidney disease, which has since been proven ineffective
Novo Nordisk overtakes SAP as Europe’s most valuable company
Novo’s market capitalisation stood at US$365 billion
